Back to homepageOur expertise in microbiology and molecular biology enables us to support the development of your candidates that contribute to the health of domestic animals or livestock through preventive or curative approaches. To ensure that your projects are carried out under the best possible conditions, our team will support you throughout your development, from the research phases to the monitoring of animal studies.
Your needs
In the context of the development of your drug candidates aimed at improving animal health, you are seeking an in vitro services provider in microbiology and molecular biology to support your projects in the design and enhancement of products at all stages. Smaltis is the ideal company to meet your needs, offering high scientific expertise and a customized approach.
Your products
- Antibiotics
- Antifungals
- Antimicrobial peptides
- Antibacterial antibodies
- Vaccine components
- Other molecules for anti-infectious purposes
- Other compounds acting on animal health through the microbiome
- Disinfectant products
The approaches you work on
Are you working on the anti-infectious axis, on modulating a microbiome, or on developing compounds used for animal vaccination? Whatever strategy you employ to bring benefits to animal health, the Smaltis team, along with its expertise, knowledge, and technologies, is at your disposal to facilitate and successfully execute your projects.
Our expertises
Our offer
At what stage are you?
| DEVELOPMENT STAGES |
1
RESEARCH & SELECTION |
2
PROOF OF CONCEPT/EFFICACY |
3
BIOPROCESSES |
4
ANIMAL STUDIES |
| OUR SERVICES |
Screening of candidates, |
Understanding of action mechanisms, |
Development and optimization of bioprocesses, |
Support for animal studies through in vitro monitoring of samples, |
Why choose Smaltis?
Our services and support enable you to supply, enhance, and secure your data within a rigorous scientific framework. We have been working for several years on various projects in animal health, and our teams of scientists are capable of discussing your objectives and recommending the most suitable and relevant manipulations for your needs. You can rely on Smaltis for complete project management, adaptation to your requirements, and guaranteed traceability of the experiments conducted.
Get in touch!
Hervé MARION, DVM
General Secretary
CEESA
As part of our European activities in the field of animal health, we entrusted Smaltis with the handling and storage of our biological samples. Their facilities provide reliable and fully controlled storage conditions, well suited to the nature and strategic value of these resources. Beyond storage, the quality of the exchanges and the follow-up provided by the Smaltis team is a real asset. Communication is smooth, information is clear, and traceability is rigorous, which greatly facilitates the long-term management of our collections. The ability to process or analyse the strains directly at Smaltis when needed further strengthens the value of this partnership. This flexibility allows us to anticipate scientific or regulatory needs while relying on a single, reliable, responsive partner with strong microbiological expertise.
Delphine GALLAND
Head of Preclinical Clinical Studies
VETOQUINOL
For the past 10 years, we have regularly turned to Smaltis for their services and expertise in microbiology, cellular biology, and molecular biology. The entrusted work focused on evaluating the efficacy and safety of various products related to infectious diseases. The smoothness of our interactions, the responsiveness of the entire team, and their adaptation to our regulatory requirements have allowed us to advance our research projects optimally. The trust we have placed in Smaltis over these 10 years has led us to include this provider among our preferred contacts.
Jérôme SCHMEISSER
Biology Lab Manager
DSM-FIRMENICH
In the context of our developments in animal health dietary supplements, we turned to SMALTIS to assess the impact of our products on the expression of genes of interest in different tissues. The molecular biology expertise of SMALTIS allows us to rely on this laboratory, whose qualitative results provide us with robust and reliable data. We also benefit from constructive exchanges with their teams to progress together throughout the project. SMALTIS thus constitutes a true extension of our R&D department, allowing us to focus on our own expertise while relying on this partner with whom we will continue to collaborate.
Stéphane KROEMER
Preclinical and Clinical trials officer
DÔMES PHARMA
In the context of our animal health activities, we needed a partner capable of retrieving, centralizing, and securing our own strain collections as well as those provided by European collaborators. Smaltis quickly addressed this need by implementing a comprehensive and reliable storage solution. Their ability to manage different types of collections streamlines our logistics and ensures the rigorous traceability we rely on. Beyond storage, being able to draw on their expertise for strain identification and characterization enables us to confidently anticipate the next steps of our projects. This collaboration strengthens our operational efficiency while safeguarding strategic biological resources for our programs. We know our strains are managed with a high level of scientific rigor and a truly valuable sense of service.
Pierre BELICHARD
CEO
ENTEROME
As part of the development of our candidate EB8018 designed to block bacteria expressing virulence factor FimH (a key inducer of the inflammatory cascade of the intestine, particularly in patients with Crohn disease), we have successively called upon the services of SMALTIS. In the preclinical phase, they first quantified in vitro the adhesion and invasion capacities of a collection of strains isolated from patients on a model of intestinal cell infection and then evaluated the impact of our molecule on these strains. The quality of the work performed, the level of expertise of the team combined with the ability to listen and adapt, led us to include SMALTIS as a service provider in our Phase 1b clinical study. The team developed a customized procedure to isolate and dissociate bacteria called "adherent" and "invasive" in intestinal biopsies, and then demonstrated the action of our EB8018 compound on these strains. SMALTIS continues to support the development of EB8018 in a phase 2a clinical trial.
Romain DAILLERE
Head of Preclinical Research - Co-founder
EVERIMMUNE
As part of the Oncobax®-AK project and the development of Live Biotherapeutic Products to potentiate the efficacy of cancer immunotherapies, we called upon Smaltis' services to characterize one of our candidate bacterial strains. The objective was to provide a complete file to the regulatory authorities regarding the characteristics of the strain, before initiating clinical studies. The Smaltis team worked hard to develop the protocols and test conditions necessary to determine the specificities of the strain of interest. The rigor shown by Smaltis' researchers, the quality and detail of the data transmitted, as well as the scientific relevance of the various characterization tests, allowed us to meet the regulatory requirements and to initiate the clinical trials with confidence. We are delighted to have collaborated with Smaltis.